Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing